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Bim Expression Is Reduced in Human Cutaneous
Melanomas
Derek L. Dai1, Yemin Wang1, Min Liu1, Magdalena Martinka2 and Gang Li1
Bim is a BH3-only protein belonging to the Bcl-2 family of apoptotic regulators. Upon activation, Bim can
antagonize all the prosurvival Bcl-2 proteins, leading to apoptosis. To investigate whether Bim plays a role in
melanoma progression, we used tissue microarray and immunohistochemistry to measure Bim expression in 52
cases of dysplastic nevi, 159 cases of primary melanomas and 52 cases of melanoma metastases, and evaluated
the prognostic value of Bim expression. Our results showed that Bim expression is reduced as melanoma
progresses. Significant differences for Bim staining pattern were observed between dysplastic nevi and
metastatic melanomas (Po0.001, w2 test), and between primary melanomas and metastatic melanomas (Po0.001,
w2 test). Moreover, reduced Bim expression is significantly correlated with poor 5-year survival of melanoma
patients but failed to be an independent prognostic factor by Cox regression analysis. Our data suggest that Bim
loss may play an important role in melanoma progression.
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INTRODUCTION
Cutaneous malignant melanoma is a deadly skin cancer,
which is derived from epidermal melanocytes. The incidence
of melanoma is increasing more rapidly than any other
tumors among Caucasian populations (Rigel et al., 1996).
Stunning reports indicated that the probability of an Amer-
ican developing melanoma during his/her lifetime leaped
from 1 in 1,500 in 1960, to 1 in 68 in 2000, and is projected
to increase to 1 in 50 by the year 2010 (Rigel et al., 1996;
Rigel, 2002). Although early melanomas are curable with
surgical excision, up to 20% of patients will develop
metastatic tumors due to its high capability of invasion and
rapid metastasis to other organs (Balch et al., 2001a;
Houghton and Polsky, 2002). Malignant melanoma is
associated with one of the highest mortality rates particularly
for advanced diseases. Patients with metastatic melanoma
have a poor prognosis, with a median survival of only 6–10
months and o5% of patients surviving more than 5 years
(Manola et al., 2000; Balch et al., 2001a; Rigel, 2002; Tsao
et al., 2004).
To date, the success of systemic therapy for melanoma
remains unsatisfactory. The main obstacle in treating
melanoma especially for advanced diseases is its resistant
characteristics to radio- and chemo-therapy (Gilchrest et al.,
1999; Li and McClay, 2002). Many chemotherapeutic agents
such as taxanes, vinca alkaloids, and platinum-associated
drugs, have failed to induce a significant response in
melanomas. Even dacarbazine, the only Food and Drug
Administration-approved drug for the treatment of malignant
melanoma, can cure only 5–10% of patients (Anderson et al.,
1995; Serrone et al., 2000; Soengas and Lowe, 2003).
Although the molecular mechanism for drug resistance in
melanoma is still poorly understood, it appears that the low
therapeutic efficacy in this disease is likely due to a relative
inability to induce apoptosis. P53, a central sensor linking
DNA damage to apoptosis, has been related to tumorigenesis
and chemoresistance in many tumor types (Fridman and
Lowe, 2003; Oren, 2003). However, unlike other tumor
types, melanoma displays a very low mutation rate of the p53
gene, suggesting that deregulation of other components of the
p53-mediated pathway may contribute to distorted apoptosis
of melanoma cells and thus the disease progression. In fact,
altered expression of upstream or downstream effectors of
p53, such as FLIP, IAP family members, BCL-2 family
members have been reported in melanoma (Irmler et al.,
1997; Grossman et al., 1999, 2001; Bush and Li, 2003;
Hakansson et al., 2003). Bim is a BH3-only protein belonging
to the Bcl-2 family with three major forms generated by
alternative splicing: BimEL, BimL, and BimS (O’Connor et al.,
1998; Bouillet et al., 2001). These isoforms differ from each
other in cytotoxicity, with BimS being the most potent. Upon
cytotoxic stimuli, Bim is activated and released from the
cytoskeleton, then translocates to the mitochondria, where it
antagonizes all the prosurvival Bcl-2 proteins, resulting in
apoptosis (Puthalakath et al., 1999; Lei and Davis, 2003;
Putcha et al., 2003; Chen et al., 2005). Recent studies linked
Bim to tumorigenesis in several cancer types. It was shown
that inactivation of even a single allele of Bim could greatly
accelerate leukemogenesis in Em-myc transgenic mice (Egle
et al., 2004). Another study by Tagawa et al. (2005) showed
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that 17% of human mantle cell lymphomas display homo-
zygous deletions of the Bim locus. Moreover, reduced Bim
protein expression was observed in 18% mesotheliomas and
19% gastric cancer biopsies (O’Kane et al., 2006; Smith et al.,
2006).
In this study, we sought to determine whether Bim is
dysregulated in the development of human melanoma. We
used tissue microarray (TMA) technology and immuno-
histochemistry to evaluate the Bim expression level in human
melanoma biopsies at different stages.
RESULTS
Clinicopathological features of TMAs
Owing to loss of biopsy cores or insufficient tumor cells
present in the cores, 52 cases of dysplastic nevi, 159 cases of
primary melanomas, and 52 cases of melanoma metastases
could be evaluated for Bim staining. For the 159 primary
melanoma cases, there were 94 male and 65 females, with
age ranging from 21 to 93 years (median¼58). For primary
melanoma staging, we used Breslow thickness (Balch et al.,
2001b) as our criteria for evaluating Bim expression: 66 tumors
were p1mm, 47 were 1.01–2mm, 24 were 2.01–4mm,
and 22 were44mm. Thirty melanomas were located in sun-
exposed sites (head and neck) and 129 were located in
sun-protected sites (other locations). Ulceration was observed
in 28 cases (Table 1).
Reduced Bim expression correlates with melanoma progression
We examined Bim expression in human melanoma TMA by
immunohistochemistry. Various levels of cytoplasmic Bim
staining were observed in nevi and melanoma biopsies
(Figure 1). Among the groups, there are marked differences in
the pattern of Bim staining, with decreased levels of
expression from dysplastic nevi to primary melanomas to
metastatic melanomas (Table 2). Significant differences for
Bim staining immunoreactivity were observed between
dysplastic nevi and metastatic melanomas (Po0.001, w2
test), and between primary melanomas and metastatic
melanomas (Po0.001, w2 test) (Table 2).
Bim expression and clinicopathological parameters
To assess whether Bim expression correlates with clinico-
pathological parameters of the patients, we examined the
expression of Bim in 159 primary melanomas at various
stages of invasion. As shown in Table 1, Bim expression was
distributed fairly evenly among the various Breslow thickness
categories (P40.05, w2 test). Tumor ulceration is often
considered as an indicator for melanoma prognosis (McGo-
vern et al., 1982). However, in our study, we did not find any
correlation between Bim expression and tumor ulceration
status (P40.05, w2 test) (McGovern et al., 1982). In addition,
we did not find correlation between Bim expression with age,
sex, or location of tumors (sun-protected vs sun-exposed)
(Table 1).
Bim expression and patient 5-year survival
To evaluate whether Bim staining might be related to
melanoma patient survival, Kaplin–Meier survival curves
were constructed using either overall or disease-specific
5-year survival of all the melanoma patients (n¼211). As
shown in Figure 2a, patients with negative, weak, moderate,
and strong Bim expression showed a 5-year overall survival
Table 1. Bim staining and clinicopathological
characteristics of 159 primary melanomas
Bim staining
Variable Negative Weak Moderate Strong Total P-value1
Age
p58 3 (4%) 32 (39%) 32 (39%) 16 (19%) 83 0.622
458 6 (8%) 29 (38%) 26 (34%) 15 (20%) 76
Gender
Male 5 (5%) 35 (37%) 35 (37%) 19 (20%) 94 0.653
Female 4 (6%) 26 (40%) 23 (35%) 12 (18%) 65
Tumor thickness (mm)
p1 4 (6%) 22 (33%) 26 (39%) 14 (21%) 66 0.428
1.01–2 1 (2%) 25 (53%) 15 (32%) 6 (13%) 47
2.01–4 2 (8%) 5 (21%) 10 (42%) 7 (29%) 24
44 4 (18%) 7 (32%) 7 (32%) 4 (18%) 22
Ulceration
Absent 8 (6%) 49 (37%) 49 (37%) 25 (19%) 131 0.779
Present 1 (4%) 12 (43%) 9 (32%) 6 (21%) 28
Site2
Sun-protected 8 (6%) 48 (37%) 47 (36%) 26 (20%) 129 0.746
Sun-exposed 1 (3%) 13 (43%) 11 (37%) 5 (17%) 30
1w2 test for the statistic analysis.
2Sun-protected sites: trunk, arm, leg, and feet. Sun-exposed sites: head
and neck.
a c
b d
Figure 1. Representative images of Bim immunohistochemical staining in
human primary melanomas. (a) Negative Bim staining; (b) weak Bim
staining; (c) moderate Bim staining; (d) strong Bim staining. Bar¼ 10 mm.
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rate of 33, 60, 71, and 73%, respectively. Similar trend was
observed in our disease-specific survival curve: patients with
negative, weak, moderate, and strong Bim expression showed
a 5-year survival rate of 39, 66, 78, and 81%, respectively
(Figure 2b). Strikingly, our data showed that reduced Bim
expression is significantly correlated with poor overall and
disease-specific patient survival (Po0.001 for both) (Figure 2).
However, in our multivariate Cox Regression analysis
including Bim expression, age, sex, thickness, ulceration,
and location of the tumors, Bim expression failed to be an
independent prognostic factor for both overall and disease-
specific 5-year survival (Table 3).
DISCUSSION
Defects in the apoptotic pathways can be the cause of cancer
development and resistance to conventional therapy. Malig-
nant melanoma is a particularly aggressive form of cancer in
this regard. Various studies have shown that BH3-only
proteins play important roles in linking various upstream
signals including the p53 pathway and oncogene-driven cell
death to the intrinsic apoptosis pathway. Upon activation,
BH3-only proteins antagonize Bcl-2-like prosurvival proteins
with their BH3 domain, resulting in the release of cytochrome
c from mitochondria and caspase cleavage (Sattler et al.,
1997; Kelekar and Thompson, 1998; Cheng et al., 2001).
Among all the BH3-only protein members, Bim has been
shown to have the ability to interact with all the prosurvival
Bcl-2 members, suggesting that it may serve as a key factor in
the event of programmed cell death and thus inhibition of
Bim function may be involved in tumorigenesis (Chen et al.,
2005). In this study, to understand better the role of Bim in
melanoma development and/or progression, we used TMA
technology and immunohistochemistry to investigate Bim
expression in pigmented skin lesions at different stages using
an antibody specific to Bim. Our results demonstrated that
Bim expression decreases as melanoma progresses from
dysplastic nevi to primary melanomas, and from primary
melanomas to metastatic melanomas (Table 2). Strikingly,
reduced Bim expression is significantly correlated with a
poorer 5-year survival of melanoma patients (Figure 2).
However, in our multivariate analysis, Bim failed to be an
independent prognostic factor for patients with primary
melanomas (Table 3). Our results provided early evidence
Table 2. Comparison of Bim staining among
subgroups of melanocytic lesions
Bim staining
Subgroups Negative Weak Moderate Strong Total
Dysplastic nevi 0 (0%) 19 (37%) 15 (29%) 18 (35%) 52
Primary melanoma 9 (6%) 61 (38%) 58 (36%) 31 (19%) 159
Metastatic melanoma 18 (35%) 21 (40%) 11 (21%) 2 (4%) 52
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Figure 2. Reduced Bim expression correlates with a worse 5-year patient
survival. Reduced Bim staining correlates with a (a) poorer overall 5-year
survival (Po0.001, log-rank test) and (b) disease-specific 5-year survival
(Po0.001, log-rank test).
Table 3. Multivariate Cox regression analysis of Bim
and tumor thickness/ulceration on 5-year patient
survival
Overall survival Disease-specific survival
Variable1
Relative
risk 95%CI2 P-value
Relative
risk 95%CI P-value
Bim 1.63 0.80–3.34 0.178 2.17 0.91–5.22 0.082
Thickness 4.06 1.92–8.58 o0.001 5.58 2.13–14.60 o0.001
Ulceration 2.92 1.43–5.98 0.003 5.14 2.14–12.31 o0.001
Location 1.63 0.74–3.62 0.229 2.57 1.00–6.60 0.050
Age 1.37 0.64–2.96 0.419 0.65 0.27–1.57 0.337
Gender 1.85 0.94–3.61 0.073 1.44 0.63–3.30 0.388
1Coding of variables: Bim was coded as 1: moderate or strong expression;
and 2: negative or weak expression. Thickness was coded as 1: p2mm;
and 2: 42mm. Ulceration was coded as 1: absent; and 2: present.
Location was coded as 1: extremities and trunk; and 2: head and neck.
Age was coded as 1:p58 years; and 2:458 years. Gender was coded as
1: male; and 2: female.
2CI: confidence interval.
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that reduced Bim expression is associated with tumor
progression and poor patient survival.
The stage-specific expression patterns of Bim observed in
our study suggest that decreased Bim expression might be a
common requirement for the transformation from benign
neoplasia to malignancies as well as from primary tumors to
metastatic disease in melanoma. Although the molecular
basis of the downregulated Bim expression in melanoma is
not clear, we speculate that it could be due to increased Bim
degradation during melanomagenesis. For example, mitogen-
activated protein kinase pathway is reported to be constitu-
tively activated in melanomas and it has been reported that
the phosphorylation of Bim accounts for the prosurvival effect
of mitogen-activated protein kinase activation (Smalley,
2003; Panka et al., 2006). Once mitogen-activated protein
kinase is activated, extracellular signal-regulated kinases 1
and 2 phosphorylate Bim at one or more serine residues,
which promote its ubiquitination and subsequent degradation
via the proteasome pathway (Luciano et al., 2003; Ley et al.,
2005). Moreover, inhibition of the mitogen-activated protein
kinase pathway results in the accumulation of Bim and its
association with the proapoptotic Bcl-2 family member Bax,
resulting in the death of the cell (Harada et al., 2004).
Another explanation of Bim loss in melanoma could be due
to gene deletion during melanoama development, as a recent
study showed that homozygous chromosome loss of 2q13
region, which leads to the loss of Bim gene, was detected in
17% human mantle cell lymphoma (Tagawa et al., 2005).
In our study, we found that reduced Bim expression
significantly correlates with 5-year survival of melanoma
patients, suggesting that Bim may serve as a therapeutic target
for melanoma. Because chemotherapy history of patients
were not available, it is not clear whether there is a strong
association between reduced Bim expression and chemore-
sistance in these patients. As melanomagenesis is a multiple-
step event in which a number of important molecular
changes may occur sequentially, dysfunction of other
components in the apoptotic pathway as well as the survival
pathway may function together with Bim loss, contributing to
melanoma development and associated drug resistance. For
example, Akt has been found to be constitutively activated in
melanoma, which leads to upregulation of nuclear factor-kB
and tumor progression (Dhawan et al., 2002). Recently, we
demonstrated that both phosphorylated Akt and integrin-
linked kinase, a direct regulator of Akt activity, are both
overexpressed in melanoma and are correlated with primary
melanoma thickness (Dai et al., 2003, 2005). As the negative
regulator of this pathway, phosphatase and tensin homolog
deleted on chromosome 10 expression was found to be
reduced in melanoma biopsies and loss of phosphatase and
tensin homolog deleted on chromosome 10 can promote
tumor growth in vivo (Stahl et al., 2003; Tsao et al., 2003). In
addition, activation of Akt signaling itself also can negatively
regulate Bim gene expression by inhibiting the forkhead
transcription factor FOXO3a (Trotman et al., 2006). Given
the fact that many factors participate in the governance of the
fate of melanoma cells, it is worth targeting multiple
molecules in different pathways as a therapeutic approach.
The data presented in this report demonstrated that
reduction of Bim expression is significantly correlated with
human melanoma progression and reduced Bim expression
correlates with a worse 5-year survival of melanoma patients.
These data, together with a recent finding that introduction of
TAT–Bim fusion protein leads to apoptosis in murine
melanoma cells both in vitro and in vivo (Kashiwagi et al.,
2007), suggest that overexpression of Bim may have a
therapeutic value in human melanoma.
MATERIALS AND METHODS
The use of human skin tissues in this study was approved by the
medical ethical committee of the University of British Columbia and
was performed in accordance with the Declaration of Helsinki
Principles.
TMA construction, immunohistochemistry of TMA, and
evaluation of immunostaining
TMA construction and immunohistochemistry of TMA were de-
scribed elsewhere (Dai et al., 2005). A polyclonal rabbit anti-Bim
antibody (NeoMarkers, Fremont, CA), which can recognize all three
Bim isoforms, was used for immunohistochemistry (1:50 dilution).
The Bim staining was examined blinded by two independent
observers (including one dermatopathologist) simultaneously, and
a consensus score was reached for each core. The level of Bim
staining was estimated semiquantitatively by using the immuno-
reactive score (IRS) (Remmele and Stegner, 1987). The IRS is
calculated by multiplying the staining intensity (graded between 0
and 3) and the percentage of positive cells (graded between 0 and 4:
0, negative; 1,o10%; 2, 10–50%; 3, 51–80%; 4,480%). It allows a
maximum value of 12. On the basis of IRS, the Bim staining pattern
was defined as: negative (IRS: 0), weak (IRS: 1–4), moderate (IRS:
5–8), and strong (IRS: 9–12). In the cases with discrepancy between
duplicated cores, the higher score from the two tissue cores was
taken as the final score.
Statistical analysis of TMA
Statistical analysis was performed with the SPSS 11.5 software (SPSS,
Chicago, IL). The w2 test was used to compare the quantitative
differences of Bim staining in different stages of melanoma
progression. The association between Bim staining and the
clinicopathological parameters of the primary melanoma patients,
including age, gender, tumor thickness, ulceration, and location,
was also evaluated by w2 test. The Kaplan–Meier method and log-
rank test were used to evaluate the correlations between
Bim expression and patient survival. Cox regression model was
used for multivariate analysis. A P-value of o0.05 was considered
significant.
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